Evolving IgAN Landscape: Persistent Unmet Need Despite Expanding Therapeutic Options (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0665; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Dual APRIL/BAFF inhibitors (e.g., atacicept, povetacicept) are viewed as highly promising, while nephrologists also consider complement inhibitors (ravulizumab, sefaxersen) and plasma-cell–targeting therapies (felzartamab, mezagitamab) as also offering potential. Conclusion Despite rapid therapeutic innovation and increasing adoption of targeted agents, IgAN remains characterized by continued unmet need, with many patients failing to achieve proteinuria targets or optimal disease control. Evolving treatment strategies and diverse pipeline mechanisms are expected to play a critical role in improving long-term renal outcomes."
Glomerulonephritis • IgA Nephropathy • Renal Disease
|
|
Jennifer Lafave; Stephanie Tomazin; Kari McCarthy
|